Share on StockTwits

Oncomed Pharmaceuticals (NASDAQ:OMED) Director Jack W. Lasersohn bought 1,045 shares of the company’s stock on the open market in a transaction dated Friday, August 15th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $17,765.00. Following the completion of the acquisition, the director now directly owns 1,045 shares in the company, valued at approximately $17,765. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Zacks downgraded shares of Oncomed Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Tuesday, August 12th. They now have a $15.00 price target on the stock. Analysts at Mizuho reiterated a “buy” rating on shares of Oncomed Pharmaceuticals in a research note on Friday, June 13th.

Oncomed Pharmaceuticals (NASDAQ:OMED) traded up 0.84% during mid-day trading on Wednesday, hitting $19.17. 41,178 shares of the company’s stock traded hands. Oncomed Pharmaceuticals has a 1-year low of $12.07 and a 1-year high of $42.34. The stock’s 50-day moving average is $21.17 and its 200-day moving average is $26.47. The company’s market cap is $570.5 million.

Oncomed Pharmaceuticals (NASDAQ:OMED) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.50. The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $21.28 million. Analysts expect that Oncomed Pharmaceuticals will post $-1.35 EPS for the current fiscal year.

OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.

Receive News & Ratings for Oncomed Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.